For Research Use Only. Not for Human Consumption.
Recorded market$54.77Recorded exact-size market estimate: 54.77 USD for one 5 mg container (10.954123 USD/mg). Arithmetic mean of 10 recorded supplier prices for this same vial or container size and formulation, with no extrapolation from other sizes. Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. Non-USD prices use ECB exchange rates dated October 9, 2026. Shipping excluded; supplier tax treatment is retained as recorded. This is a dated price comparison, not a former Peptide Serum price or an assurance of potency, purity, dosing or medical equivalence.Public price$86.89Member price$78.20No member savings vs. this market reference
Long-acting GHRH analog for endocrine research.
Exact-size price research
Supplier observation dates: Oct 10, 2026 UTC to Oct 11, 2026 UTC. This reference uses recorded prices for the same 5 mg vial or container and formulation. No prices are extrapolated from smaller or larger vials. Peptide Serum member unit prices refresh from the current catalog. Paid PRO membership is required for member pricing.
$15.64/mg
Peptide Serum reference: Member unit price (USD), available with verified paid PRO membership; excludes shipping and applicable taxes. Read from catalog: Oct 23, 2026 04:32 UTC. 1 x 5 mg = 5 mg total.
Source: PeptideSerum-exact-size-market-comparison.xlsx. One selected single-container price per supplier domain, for the same labeled vial size and formulation. Blends match recorded component amounts. The arithmetic mean uses the first ten selected supplier prices in recorded Google discovery order, or the true smaller sample when ten could not be found. No size scaling, mg-to-IU conversion, pack discount or minimum price range is substituted.
The green percentage, when shown, compares the member price for every visitor: (recorded exact-size market average minus Peptide Serum member price) divided by the recorded market average. Unrounded values are used and the percentage is rounded down to one decimal. It is omitted when the member price is equal to or above the reference or the refreshed snapshot cannot be confirmed. Member pricing requires verified paid PRO membership.
These are dated price observations, not live available supplier offers. Shipping is excluded. Supplier tax treatment is retained as recorded and can differ. Memberships, clinical qualifications, ancillary supplies and availability can affect comparability; source notes retain these limitations. Some observations were sold out. Seller domains may be correlated through one manufacturer. This is not a revenue-ranked or complete-market survey.
Non-USD native prices are converted using ECB reference rates dated October 9, 2026. Recorded exchange-rate source. Original prices and currencies are shown below. Currency conversion does not make tax treatment or purchasing conditions identical.
| Source / recorded date | Exact vial / native price | USD per mg | Recorded coverage / conditions |
|---|---|---|---|
| Pioneer Peptide Oct 10, 2026 UTC | One 5 mg container; 45.00 CAD | $6.33/mg | powder; publicly listed Exact5mg withDAC lyophilized single vial; CAD explicitly in publisher Offer. Public45CAD sale. Age notice not accepted. Price observation; no COA authentication is implied by inclusion. |
| PeakForm Peptides specifications Oct 10, 2026 UTC | One 5 mg container; 55.00 USD | $11.00/mg | powder; publicly listed Product graphic visibly states CONTENTS:CJC-1295WithDAC5mg and Form:Lyophilized Powder. One-product USD55. Specification table incorrectly says5mg/perML in3mL vial; exact5mg graphic used, conflict flagged. Screenshot peakform-dac-label.png. Price observation; no COA authentication is implied by inclusion. |
| Northline Labs Oct 10, 2026 UTC | One 5 mg container; 89.99 USD | $18.00/mg | powder; publicly listed USD89.99 exact5mg standalone withDAC lyophilized vial; automaticpublicsale. Price observation; no COA authentication is implied by inclusion. |
| Core Peptides Oct 10, 2026 UTC | One 5 mg container; 52.00 USD | $10.40/mg | powder; publicly listed ExactUSD52 withDAC5mg lyophilized singlevial; volume prices excluded. Distinct domain retained; Core/Biotech catalogs may be correlated. Price observation; no COA authentication is implied by inclusion. |
| Luxe Peptides Oct 10, 2026 UTC | One 5 mg container; 45.00 USD | $9.00/mg | powder; publicly listed ExactUSD5mg withDAC45 variant, lyophilizedglassvial; optional buy2 promotionexcluded and assayoverfill notsize. Price observation; no COA authentication is implied by inclusion. |
| Red Rock Peptides Oct 10, 2026 UTC | One 5 mg container; 62.00 USD | $12.40/mg | powder; publicly listed ExactUSD62 withDAC5mg singlelyophilizedvial,4instock. Couponexcluded. Price observation; no COA authentication is implied by inclusion. |
| Cell Peptides Oct 10, 2026 UTC | One 5 mg container; 49.00 USD | $9.80/mg | powder; publicly listed ExactwithDAC5mg standalone vial49USD (visible USDcurrency selector); expandedlyophilizedstorage and dry5mg reconstitutionparagraph confirmform. Volumediscounts excluded. Price observation; no COA authentication is implied by inclusion. |
| Direct Doctor Supply Oct 11, 2026 UTC | One 5 mg container; 54.00 USD | $10.80/mg | powder; coming soon Exact5mg withDAC, lyophpowder; oneNoveravialphoto/noindicatedkit supportsinferredsingle. Public54USDmappedOffer, visibleComingsooncontrols overrideincorrectInStockschema. Loginonlyforstocknotification, publiccatalogopen; noentrygate. ManufacturerNovera shared with otherretailers; countretailersnotindependentmanufacturers. Price observation; no COA authentication is implied by inclusion. |
| Direct SARMs Oct 11, 2026 UTC | One 5 mg container; 59.88 USD | $11.98/mg | powder; public orderable Observed Google category→ownvial page. Selected5mg vial singlevial radio/q1, current59.88USD explicitUSDselector; imageupdates5mgDAC. Ownform sterileglassvial lyophpowder. OthergalleryaltNoDAC flaggedgenericcrossimages; selectedimage/titlewithDACconcordant. Automaticcurrentprice; firstordercoupon/multi-vialkits/spenddiscountnotused. Openafterstablescreenshot. Price observation; no COA authentication is implied by inclusion. |
| Northern Peptides Oct 11, 2026 UTC | One 5 mg container; 70.00 CAD | $9.84/mg | lyophilized powder; In stock Nominal 5mg vial, CAD70. Publisher COA summary AVG MASS1.93mg conflicts with label; comparison uses advertised nominal size only. Price observation; no COA authentication is implied by inclusion. |
Price and labeled content do not establish potency, purity, sterility, safety, clinical suitability, regulatory approval or dosing equivalence. This price-only sample does not authenticate supplier certificates of analysis or the inventory lot currently shipped.
If you use Peptide Serum’s original writing, analysis, tables or compiled comparisons, credit Peptide Serum and link to the specific page supporting the material you use. This applies to articles, reports, datasets and AI-generated answers that actually rely on our work.
Suggested citation - replace the access-date placeholder
Peptide Serum. “CJC-1295 with DAC – 5 mg | Catalog & Research – Peptide Serum.” https://peptideserum.com/product/cjc-1295-with-dac-5-mg/ Accessed [your access date].
Source page: https://peptideserum.com/product/cjc-1295-with-dac-5-mg/
A growth-hormone-releasing-hormone analog bearing a drug-affinity complex that extends its active life in preclinical endocrine research.
Supplied sealed for laboratory handling. Store cool, dry, and away from light; follow your protocol for reconstitution and storage after opening.
For in-vitro laboratory research only. Not for human or veterinary use.
Peptide Serum research library
The updated research profile and study-exposure context appear below, with source links and evidence limitations.
CJC-1295 with DAC refers to the albumin-binding, long-acting research construct associated with the original CJC-1295 studies. Its prolonged hormone effects are experimentally documented. They should not be confused with demonstrated clinical benefits or transferred to a product lacking that modification.
DAC describes the modification used to extend persistence through albumin binding. It changes the exposure profile and is not merely a packaging or salt label.
The clinical papers do not fully specify every salt-form detail. A claim of identical study material therefore requires more than matching CJC-DAC on a label.
Human research characterized prolonged exposure and GH/IGF-1 responses. A separate pulsatility experiment found that the pattern of GH pulses persisted while trough levels increased. This is a specific physiological observation, not proof that the intervention simply restores a youthful or harmless hormone pattern.
| Study and design | Finding | What it does not establish |
|---|---|---|
| Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Randomized placebo-controlled single- and repeat-exposure studies in healthy adults Reading scope: PubMed abstract and bibliographic record; not full-text review |
The estimated half-life was 5.8–8.1 days, and repeated exposure produced persistent IGF-1 elevation. | Persistence and accumulation describe pharmacokinetics and pharmacodynamics, not an optimal personal schedule or proven clinical benefit. |
| Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
Overnight GH-sampling study in healthy adult men before and after the long-acting analogue Reading scope: PubMed abstract and bibliographic record; not full-text review |
GH pulsatility remained detectable, while basal GH and mean hormone measures increased. | Preserved pulses did not mean unchanged secretion: trough levels rose. The study did not measure longevity, recovery or athletic performance. |
For the differences between a mechanism, a biomarker and a clinical outcome, see the evidence-reading guide.
Half-life is the time scale for a concentration to decline; it is not a countdown to a safe next exposure. Repeated exposures can accumulate, and downstream hormone effects have their own time course.
A mechanism that uses endogenous secretion can still change the magnitude and duration of hormone exposure. Describing it as natural does not settle its benefit–risk balance.
The trials provide a reason to distinguish DAC-containing material from shorter-acting analogues. They do not establish that greater persistence is desirable for every clinical purpose.
The FDA December 2024 review describes frequent local reactions and reports systemic symptoms in the underlying early studies. The absence of a serious event in a small trial should not be rewritten as absence of side effects.
The clinical evidence does not establish long-term safety of sustained GH/IGF-1 elevation or a safe repeated-use pattern outside the studied setting.
Keep the measured compound half-life separate from the duration of GH or IGF-1 changes. They are related but different observations.
Do not use the original study’s persistence to calculate a regimen for no-DAC material, or vice versa. Salt form, construct and actual exposure need to be matched first.
Match any reported amount or concentration to the exact material, route, population and duration in the original experiment. Read the guide to mass, volume and concentration for the meaning of common units. A calculation cannot establish an appropriate treatment or validate an untested formulation.
Verify the albumin-binding modification and full sequence through appropriate identity documentation, with the chemical form explicitly reported.
Ask whether the assay identifies the complete modified peptide rather than simply reporting a peak percentage. A label claim of extended action is not a clinical quality test.
Keep the clinical evidence and the supplier evidence separate. Use the report-verification steps to check the issuer and the batch questions to connect a tested sample with the product offered. Compare prices using the delivered-cost method rather than an isolated discount or purity percentage.
Peptide Serum operates a store as well as this research library. The supplier directory contains imported seller information; a listing is not laboratory certification. Read how this library is prepared and evaluate the documentation for the exact lot offered. A seller rating does not establish clinical safety or effectiveness.
No. The study found increased trough and mean GH despite preserved pulse pattern. That distinction is essential to interpreting the result.
No. A measured half-life describes elimination under study conditions. Choosing an exposure schedule requires safety and efficacy evidence beyond that number.
This companion to the CJC-1295 with DAC research profile explains how to interpret experimental quantities. It provides no personal-use regimen.
Keep the measured compound half-life separate from the duration of GH or IGF-1 changes. They are related but different observations.
Do not use the original study’s persistence to calculate a regimen for no-DAC material, or vice versa. Salt form, construct and actual exposure need to be matched first.
Find the tested material, formulation, route, study population, comparison group and observation period in the original paper. Exposure in a cell system or animal model does not supply a human starting amount, schedule or route.
Mass describes an amount of material; concentration describes that amount per final solution volume. One milligram equals 1,000 micrograms. Neither a vial label nor arithmetic establishes identity, stability, sterility or an appropriate use.
Read the units reference and the study summaries and their limitations. Use the original methods for the precise experimental conditions; do not transfer a reported amount between different materials or study models.
The main profile links the selected primary sources, distinguishes the study designs and explains what the findings cannot show. A trial registration is a research plan, not a published result.
Reviews
There are no reviews yet.